Mylan's Beat Lifts Hopes That Worst Is Over for Generic Drugs

(Bloomberg) -- Mylan NV’s quarterly earnings beat estimates by the most in nearly two years, a sign the drugmaker may be turning a corner in the struggling U.S. generics market.
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.